May 19, 2026
john-wilkerson-avatar-teal
Washington Correspondent, D.C. Diagnosis Writer

Would you rather get squeaky cheese curds from your MAHA senator or a fake subpoena and Tylenol from your smartalec Kennedy cousin? What I’d like is some news tips at John.Wilkerson@statnews.com or John_Wilkerson.07 on Signal.

politics

Cassidy lost. Now what?

Sen. Bill Cassidy’s (R-La.) primary loss is a win for MAHA, Chelsea Cirruzzo reports, but it’s just one of multiple changes in dynamics that could either make life easier or more difficult for health secretary Robert F. Kennedy Jr. and the Trump administration.

In the short term, Cassidy could prove to be an even bigger headache, as he will be free to vote his conscience. Even when he was worried about reelection, Cassidy made life difficult for the administration at times.

He reluctantly voted to confirm Kennedy under intense pressure from the White House and drew attention to Kennedy’s anti-vaccine statements in the process. Kennedy and Trump also blamed the senator for the withdrawal of MAHA mom Casey Means as surgeon general nominee, though Means blamed Sen. Lisa Murkowski (R-Alaska).

However, Cassidy’s main reservation with MAHA is its stance against vaccines, and the administration is trying to keep a low profile on vaccine policy until the midterms are over anyway. On issues of healthy diet, most-favored nation drug prices, health savings account reforms, and abortion, he’s in line with the administration.

Many of Kennedy’s vaccine policies were stalled by a federal judge in March. David Mansdoerfer, a former deputy assistant secretary at HHS during Trump’s first term, said it will be easier to revive those efforts next year without Cassidy in the way.

Cassidy chairs the health committee, and it’s not clear who will replace him. The three most senior Republican committee members – Sens. Rand Paul (Ky.), Susan Collins (Maine), and Lisa Murkowski (Ala.) – already have chairmanships, but they could switch for health. Sen. Roger Marshall (R-Kan.) is the most senior member who isn’t already a chair of another committee.

The retirement of Sen. Mitch McConnell (Ky.), the only Republican to vote against Kennedy’s confirmation, will also create an important absence. Both he and Cassidy are expected to be replaced by senators who are unlikely to buck the administration.

Senate Appropriations Committee Chair Susan Collins (R-Maine), who fought against the administration’s impoundments of health research funding, faces a tough reelection this year, but if she loses, she would be replaced by a Democrat. Sen. Thom Tillis (R-N.C.), who is retiring, also has been wary of MAHA’s vaccine policies, but he also might be replaced by a Democrat.

In general, the remaining Republicans in the Senate are likely to back Kennedy and Trump, but the party’s majority might narrow or evaporate in the upcoming election.



drug pricing

More than 600

That’s how many generic drugs will be added to TrumpRx thanks to a partnership with entrepreneur Mark Cuban, Amazon Pharmacy, and GoodRx, Chelsea and Daniel Payne report.

The new partnerships could make the president’s namesake website more useful to consumers. Many of the 74 brand medications on TrumpRx were already available as generics for far less. TrumpRx also has far fewer drugs available than counterparts like Cost Plus and GoodRx.

Read more.


fda

Fallout at FDA

Several FDA officials either departed or were reassigned following the resignation of Marty Makary, Lizzy Lawrence reports.

Chief among them was Tracy Beth Høeg, who had been the acting director of the agency’s drug center.

Read more to learn about the reshuffle.


medicare drug price negotiation

Lightly tapping the final nail in the coffin.

Brand drugmakers’ legal campaign against Medicare drug price negotiation has been going poorly for years. On Monday, it got worse.

The Supreme Court declined to hear six lawsuits against the law.

There are still some lawsuits pending before lower courts. If any of those were to be decided in favor of the drug industry, there’s a chance the Supreme Court might agree to hear the case. But the high court’s rejection of industry challenges makes it riskier for lower courts to rule against the Medicare program.

Read more.


insurance

Choice and consequence

The Trump administration issued a regulation on Friday that allows insurers to sell bare-bones coverage with lower monthly premiums and fewer consumer protections, Tara Bannow reports.

The administration hopes that allowing catastrophic plans will cushion premium payment increases that followed the expiration of enhanced premium subsidies. In return, catastrophic plan enrollees will have to pay deductibles that, if the administration gets its way, will be $17,500 for an individual and $35,000 for a family in 2028, according to a report from Veda Partners, an investment adviser.

Read more about the various changes to the rules.


infectious disease

Ebola update

The Trump administration banned entrance to foreign travelers who have been in the Democratic Republic of the Congo, Uganda, or South Sudan in the past 21 days, according to Annalisa Merelli and Helen Branswell.

The CDC order follows the confirmation of infection in an American doctor working in the outbreak zone.

This is the first time the U.S. has imposed a travel ban in response to an Ebola outbreak. Read more for why travel bans might make containing the virus more difficult.


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

What we’re reading

  • Texas is opening up a detransition clinic, STAT
  • Abortion pill lawsuit leaves Trump silent, and in a political bind, The New York Times